Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

HAEMOPHILIA. 2024 [Epub ahead of print].

International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal

HAEMOPHILIA. 2024 [Epub ahead of print].

Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
Beckmann L, Faizy T, Flottmann F, Fiehler J, Bokemeyer C, Well L, Beitzen-Heineke A, Langer F
HAMOSTASEOLOGIE. 2024.

Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany
Bidlingmaier C, Heller C, Langer F, Miesbach W, Scholz U, Oldenburg J, Nüesch E, Palmborg H, Santagostino E, Tiede A
RES PRACT THROMB HAE. 2024;8(5):102482.

Comparison of assays measuring extracellular vesicle-tissue factor in plasma samples: Communication from the ISTH SSC Subcommittee on Vascular Biology
Bonifay A, Mackman N, Hisada Y, Sachetto A, Hau C, Gray E, Hogwood J, Aharon A, Badimon L, Barile L, Baudar J, Beckmann L, Benedikter B, Bolis S, Bouriche T, Brambilla M, Burrello J, Camera M, Campello E, Ettelaie C, Faille D, Featherby S, Franco C, Guldenpfennig M, Hansen J, Judicone C, Kim Y, Kristensen S, Laakmann K, Langer F, Latysheva N, Lucien F, de Menezes E, Mullier F, Norris P, Nybo J, Orbe J, Osterud B, Paramo J, Radu C, Roncal C, Samadi N, Snir O, Suades R, Wahlund C, Chareyre C, Abdili E, Martinod K, Thaler J, Dignat-George F, Nieuwland R, Lacroix R
J THROMB HAEMOST. 2024;22(10):2910-2921.

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren
Eichler H, Albisetti M, Halimeh S, Knöfler R, Königs C, Langer F, Miesbach W, Oldenburg J, Scholz U, Streif W, Klamroth R
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

G protein coupled receptor transcripts in human immune cells and platelets
Hansen A, Martin D, Langer F, Harrison K, Kehrl J, Cicala C, Martinelli E, Brownstein M, Mezey E
SCI DATA. 2024;11(1):1040.

Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick
Harenberg J, Gosselin R, Cuker A, Becattini C, Pabinger I, Poli S, Weitz J, Ageno W, Bauersachs R, Ćelap I, Choi P, Douketis J, Douxfils J, Elalamy I, Fareed J, Falanga A, Favalor E, Gerotziafas G, Herkner H, Hetjens S, Klamroth R, Heubner L, Langer F, Lip G, Mac Grory B, Margetić S, Merrelaar A, Pikta M, Renne' T, Schwameis M, Schulman S, Strbian D, Tafur A, Violi F, Vassart J, Walenga J, Weiss C
THROMB HAEMOSTASIS. 2024;124(8):770-777.

Clinical guideline on reversal of direct oral anticoagulants in patients with life-threatening bleeding: use of a urine dipstick
Harenberg J, Langer F, Koscielny J
EUR J ANAESTH. 2024;41(9):713-714.

Effect of factor XI inhibition on tumor cell-induced coagulation activation
Mäder J, Rolling C, Voigtländer M, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Beckmann L, Langer F
J THROMB HAEMOST. 2024;22(1):199-212.

Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)
Marquardt N, Langer F, Holstein K, Álvarez Román M, Núñez Vázquez R, Miljić P, Drillaud N, Ardillon L, Lehtinen A, Santoro R, Napolitano M, Siragusa S, Gidley G, Jansen M, Knaub S, Oldenburg J
THER ADV HEMATOL. 2024;15:20406207241300040.

Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice;INSIGHTS-SVT study
Noppeney T, Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Pittrow D, Klotsche J, Gerlach H, Bauersachs R
J VASC SURG-VENOUS L. 2024;12(6):101917.

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)
Parmentier S, Koschmieder S, Henze L, Griesshammer M, Matzdorff A, Bakchoul T, Langer F, Alesci R, Duerschmied D, Thomalla G, Riess H
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management
Pose R, Knipper S, Ekrutt J, Kölker M, Tennstedt P, Heinzer H, Tilki D, Langer F, Graefen M
ASIAN J UROL. 2024;11(1):42-47.

Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis
Reis S, Faske A, Monsef I, Langer F, Müller O, Kranke P, Meybohm P, Weibel S
THROMB RES. 2024;238:141-150.

Reflections on World Thrombosis Day 2024
Rigby A, Albisetti M, Favaloro E, Koenen R, Langer F, Lip G, Rühl H, Weber C
THROMB HAEMOSTASIS. 2024 [Epub ahead of print].

Circulating Tumor Cells and Thromboembolic Events in Patients with Glioblastoma
Rolling C, Mohme M, Bokemeyer C, Westphal M, Riethdorf S, Lamszus K, Pantel K, Klingler F, Langer F
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

Expression and Release of Tumor Cell Tissue Factor Triggers Recurrent Thromboembolism in a Patient with Endometrial Cancer
Beckmann L, Lennartz M, Poch A, Holstein K, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2023;43(4):289-296.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K
ANN ONCOL. 2023;34(5):452-467.

Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease
Huckhagel T, Atlihan G, Langer F, Flitsch J, Rotermund R
SCI REP-UK. 2023;13(1):3217.

Grundlagen zur Anwendung von Andexanet
Koscielny J, Birschmann I, Bauersachs R, Trenk D, Langer F, Möhnle P, Beyer-Westendorf J
HAMOSTASEOLOGIE. 2023;43(6):398-409.

Editorial commentary: A one-fits-all approach to cancer-associated thrombosis – Are we there yet?
Langer F
TRENDS CARDIOVAS MED. 2023;33(6):344-345.

Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
Langer F, Quick H, Beitzen-Heineke A, Janjetovic S, Mäder J, Lehr C, Bokemeyer C, Kuta P, Renné T, Fiedler W, Beckmann L, Klingler F, Rolling C
THROMB RES. 2023;229:155-163.

Correction to: Role of prothrombin 19,911 A > G polymorphism, blood group and male gender in patients with venous thromboembolism: results of a german cohort study
Limperger V, Kenet G, Kiesau B, Köther M, Schmeiser M, Langer F, Juhl D, Shneyder M, Franke A, Klostermeier U, Mesters R, Rühle F, Stoll M, Steppat D, Kowalski D, Rocke A, Kuta P, Bajorat T, Torge A, Neuner B, Junker R, Nowak-Göttl U
J THROMB THROMBOLYS. 2023;56(1):212.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12-Month Results of the INSIGHTS-SVT Study
Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow D, Klotsche J, Gerlach H, Bauersachs R
EUR J VASC ENDOVASC. 2023;66(5):697-704.

Absence of Malaria-Associated Coagulopathy in Asymptomatic Plasmodium falciparum Infection: Results From a Cross-sectional Study in the Ashanti Region, Ghana
Rolling C, Phillips R, Abass K, Ken Adu Poku J, Osei-Mireku S, Osei-Wusu B, Thompson W, Vinnemeier C, Huebl L, Langer F, Francke P, Kuta P, Konrath S, Renné T, Tannich E, Rolling T, Heinemann M
OPEN FORUM INFECT DI. 2023;10(3):ofad074.

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure
Schönborn L, Esteban O, Wesche J, Dobosz P, Broto M, Rovira Puig S, Fuhrmann J, Torres R, Serra J, Llevadot R, Palicio M, Wang J, Gordon T, Lindhoff-Last E, Hoffmann T, Alberio L, Langer F, Boehme C, Biguzzi E, Grosse L, Endres M, Liman T, Thiele T, Warkentin T, Greinacher A
BLOOD. 2023;142(26):2305-2314.

SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review
Afshar Z, Barary M, Babazadeh A, Hosseinzadeh R, Alijanpour A, Miri S, Sio T, Sullman M, Carson-Chahhoud K, Langer F, Ebrahimpour S
REV MED VIROL. 2022;32(4):.

Haemostaseological pearls
Albisetti M, Langer F, Rühl H
HAMOSTASEOLOGIE. 2022;42(3):163-164.

Rivaroxaban bei tumorassoziierter venöser Thromboembolie
Bauersachs R, Voigtländer M, Langer F
DEUT MED WOCHENSCHR. 2022;147(23):1545-1551.

Purpura Fulminans Triggered by the Formation of Anti-Endothelial Autoantibodies in a Patient with Chronic Lymphocytic Leukemia
Beckmann L, Lennartz M, Beitzen-Heineke A, Voigtländer M, Rolling C, Holstein K, Bokemeyer C, Amirkhosravi A, Langer F
Ann Hematol Oncol. 2022;9(1):.

Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms
Beckmann L, Mäder J, Voigtlaender M, Klingler F, Schulenkorf A, Lehr C, Regenhardt J, Bokemeyer C, Ruf W, Rolling C, Langer F
THROMB RES. 2022;220:48-59.

Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources
Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin T
J THROMB HAEMOST. 2022;20(1):149-156.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al
Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin T
J THROMB HAEMOST. 2022;20(2):542-543.

Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy
Greinacher A, Langer F, Schonborn L, Thiele T, Haddad M, Renne T, Rollin J, Gruel Y, Warkentin T
HAEMATOLOGICA. 2022;107(5):1219-1221.

The Bone Microarchitecture Deficit in Patients with Hemophilia Is Influenced by Arthropathy, Hepatitis C Infection, and Physical Activity
Holstein K, Witt L, Matysiak A, Schmidt C, Barvencik F, Amling M, Rolvien T, Langer F
THROMB HAEMOSTASIS. 2022;122(5):692-702.

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination
Hosseinzadeh R, Barary M, Mehdinezhad H, Sio T, Langer F, Khosravi S
RES PRACT THROMB HAE. 2022;6(4):.

Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia
Janjetovic S, Rolling C, Budde U, Schneppenhem S, Schafhausen P, Peters M, Bokemeyer C, Holstein K, Langer F
THROMB RES. 2022;218:35-43.

TEMPORARY REMOVAL OC-02: Outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
Langer F, Gerlach H, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R
THROMB RES. 2022;213 Suppl 2:S1-S2.

Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
Langer F, Gerlach H, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R
THROMB RES. 2022;220:145-152.

Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism
Limperger V, Torge A, Kiesau B, Langer F, Kenet G, Mesters R, Juhl D, Stoll M, Shneyder M, Kowalski D, Bajorat T, Rocke A, Kuta P, Lasarow L, Spengler D, Junker R, Nowak-Göttl U
BLOOD CELL MOL DIS. 2022;94:.

PO-31: The small-molecule FXIa inhibitor, BMS-26208, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression
Mäder J, Voigtländer M, Rolling C, Quick H, Schulenkorf A, Lehr C, Bokemeyer C, Beckmann L, Langer F
THROMB RES. 2022;213(Suppl 2):.

Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)
Malin J, Spinner C, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S
INFECTION. 2022;50(1):107-108.

Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)
Malin J, Spinner C, Janssens U, Welte T, Weber-Carstens S, Schälte G, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Krawczyk M, Nehls W, Fichtner F, Laudi S, Stegemann M, Skoetz N, Nothacker M, Marx G, Karagiannidis C, Kluge S
INFECTION. 2022;50(1):93-106.

Die akute Promyelozytenleukämie - ein hämatologischer Notfall
Modemann F, Ghandili S, Zhurba I, Langer F, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(12):10–15.

Management of Patients Receiving Direct Oral Anticoagulants Scheduled for Radical Prostatectomy: An Update of a Prospective Assessment
Pose R, Langer F, Tennstedt P, Graefen M, Isbarn H
EUR UROL FOCUS. 2022;8(1):128-133.

Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors
Voigtlaender M, Edler C, Gerling M, Schädler J, Ondruschka B, Schröder A, Sperhake J, Ehrhardt S, Wang L, Haddad M, Kiencke V, Renné T, Roedl K, Kluge S, Wichmann D, Langer F
THROMB RES. 2022;218:171-176.

Management of Vascular Thrombosis in Patients with Thrombocytopenia
Voigtlaender M, Langer F
HAMOSTASEOLOGIE. 2022;42(1):19-28.

62/w mit rezidiviertem Ovarialkarzinom und Luftnot
Voigtländer M, Langer F
ONKOLOGE. 2022;2022(28):144-149.

Gerinnungsstörungen bei Tumorerkrankungen
Voigtländer M, Langer F
DERMATOLOGIE. 2022;73(10):809–819.

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT)
Bauersachs R, Gerlach H, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E
EUR J VASC ENDOVASC. 2021;62(2):241-249.

Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts
Beckmann L, Rolling C, Voigtländer M, Mäder J, Klingler F, Schulenkorf A, Lehr C, Bokemeyer C, Ruf W, Langer F
CANCERS. 2021;13(16):3941.

Monocyte activation and acquired autoimmune protein S deficiency promote disseminated intravascular coagulation in a patient with primary antiphospholipid syndrome
Beckmann L, Voigtländer M, Holstein K, Lennartz M, Schneider S, Haddad M, Renné T, Bokemeyer C, Rolling C, Langer F
RES PRACT THROMB HAE. 2021;5(5):.

Myeloperoxidase has no effect on the low procoagulant activity of silica-free DNA
Beckmann L, Voigtländer M, Rolling C, Schulenkorf A, Bokemeyer C, Langer F
THROMB RES. 2021;2021(203):36-45.

Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation
Englert H, Rangaswamy C, Deppermann C, Sperhake J, Krisp C, Schreier D, Gordon E, Konrath S, Haddad M, Pula G, Mailer R, Schlüter H, Kluge S, Langer F, Püschel K, Panousis K, Stavrou E, Maas C, Renné T, Frye M
EBIOMEDICINE. 2021;67:.

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation
Janjetovic S, Beckmann L, Holstein K, Rolling C, Thiele B, Schafhausen P, Schön G, Bokemeyer C, Langer F, Voigtlaender M
THROMB RES. 2021;198:55-61.

Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO)
Kirschner M, do Ó Hartmann N, Parmentier S, Hart C, Henze L, Bisping G, Griesshammer M, Langer F, Pabinger-Fasching I, Matzdorff A, Riess H, Koschmieder S
CANCERS. 2021;13(12):2905.

S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19
Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Spinner C, Malin J, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Rabe K, Hoffmann F, Böttiger B, Weinmann-Menke J, Kersten A, Berlit P, Haase R, Marx G, Karagiannidis C
PNEUMOLOGIE. 2021;75(2):88-112.

Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study
Limperger V, Kenet G, Kiesau B, Köther M, Schmeiser M, Langer F, Juhl D, Shneyder M, Franke A, Klostermeier U, Mesters R, Rühle F, Stoll M, Steppat D, Kowalski D, Rocke A, Kuta P, Bajorat T, Torge A, Neuner B, Junker R, Nowak-Göttl U
J THROMB THROMBOLYS. 2021;51(2):494-501.

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf R, Pötzsch B, Greinacher A
HAMOSTASEOLOGIE. 2021;41(3):184-189.

Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19)
Paulsen F, Schaefers C, Langer F, Frenzel C, Wenzel U, Hengel F, Bokemeyer C, Seidel C
BLOOD. 2021;138(11):996-999.

Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study
Springer A, Schleberger R, Oyen F, Hoffmann B, Willems S, Meyer C, Langer F, Schnabel R, Kirchhof P, Schneppenheim R, Lemoine M
CLIN APPL THROMB-HEM. 2021;27:10760296211021171.

Coagulation Disorders: Manifestations in the Gastrointestinal Tract
Fischbach W, Germer T, Langer F, Mössner J
VISC MED. 2020;36(4):288-291.

LPS-induced expression and release of monocyte tissue factor in patients with haemophilia
Holstein K, Matysiak A, Witt L, Sievers B, Beckmann L, Haddad M, Renné T, Voigtländer M, Langer F
ANN HEMATOL. 2020;99(7):1531-1542.

Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 – 3. Version: S1-Leitlinie
Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Salzberger B, Gastmeier P, Langer F, Wepler M, Westhoff M, Pfeifer M, Hoffmann F, Böttiger B, Marx G, Karagiannidis C
ANAESTHESIST. 2020;69(9):653-664.

Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis
Langer F, Kluge S, Klamroth R, Oldenburg J
HAMOSTASEOLOGIE. 2020;40(3):264-269.

64(th) Annual Congress of the Gesellschaft fur Thrombose- und Hamostaseforschung e.V. in Bremen: Novel Concepts for a Lifetime Challenge
Langer F, Renné T
HAMOSTASEOLOGIE. 2020;40(1):9-11.

64th Annual Congress of the Gesellschaft für Thrombose- und Hämostaseforschung e.V. in Bremen (Part II)
Langer F, Renné T
HAMOSTASEOLOGIE. 2020;40(2):143-144.

Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?
Lippi G, Langer F, Favaloro E
SEMIN THROMB HEMOST. 2020;46(4):457-464.

Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism
Matzdorff A, Langer F
HAMOSTASEOLOGIE. 2020;40(5):655-661.

Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures
Rolling C, Tomada J, Frölich A, Holst B, Holstein K, Voigtländer M, Janjetovic S, Haddad M, Renné T, Fiehler J, Bokemeyer C, Rolling T, Langer F
CLIN CHEM LAB MED. 2020;59(2):383-392.

Effect of myeloperoxidase on the anticoagulant activity of low-molecular-weight heparin and rivaroxaban in an in-vitro tumor model
Voigtländer M, Beckmann L, Schulenkorf A, Sievers B, Rolling C, Bokemeyer C, Langer F
J THROMB HAEMOST. 2020;18(12):3267-3279.

Therapie und Prophylaxe der tumorassoziierten venösen Thromboembolie
Voigtländer M, Langer F
InFo Hämatologie + Onkologie. 2020;(06/2020):.

Treatment of the antiphospholipid syndrome with direct oral anticoagulants Position statement of German societies
Bauersachs R, Langer F, Kalka C, Konstantinides S, Klamroth R, Oldenburg J, Schellong S, Scholz U, Stücker M, Lindhoff-Last E
VASA. 2019;48(6):483-486.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment
Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H
WORLD J UROL. 2019;37(12):2657-2662.

Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism
Beyer-Westendorf J, Klamroth R, Kreher S, Langer F, Matzdorff A, Riess H
DTSCH ARZTEBL INT. 2019;116(3):31-38.

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren
Eichler H, Pedroni M, Halimeh S, Königs C, Langer F, Miesbach W, Oldenburg J, Scholz U, Streif W, Klamroth R
HAMOSTASEOLOGIE. 2019;39(4):311-321.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases
Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2019;39(3):294-297.

Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2019;39(1):67-75.

Antikoagulatorische Therapie bei onkologischen Patienten
Voigtländer M, Lennartz M, Yamamura J, Langer F
J Onkol - Z Onkol Fortb. 2019;2019(1):62-70.

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2018;38(3):150-157.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
ANAESTHESIST. 2018;67(8):599-606.

Überbrückende Antikoagulation bei Patienten unter Vitamin-K-Antagonisten: Eine Bestandsaufnahme
Schellong S, Riess H, Spannagl M, Omran H, Schwarzbach M, Langer F, Gogarten W, Bramlage P, Bauersachs R
INTERNIST. 2018;59(7):744-752.

Management of cancer-associated venous thromboembolism - a case-based practical approach
Voigtlaender M, Langer F
VASA. 2018;47(2):77-89.

Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis
Bauersachs R, Gerlach H, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E
J VASC SURG. 2017;5(4):553-560.e1.

Myeloperoxidase Is a Negative Regulator of Phospholipid-Dependent Coagulation
Beckmann L, Dicke C, Spath B, Lehr C, Sievers B, Klinke A, Baldus S, Rudolph V, Langer F
THROMB HAEMOSTASIS. 2017;117(12):2300-2311.

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)
Miesbach W, Reitter-Pfoertner S, Klamroth R, Langer F, Wolf H, Tiede A, Siegmund B, Scholz U, Müller P, Eichler H, Pabinger I
HAEMOPHILIA. 2017;23(5):721-727.

Tissue Factor Prothrombotic Activity Is Regulated by Integrin-arf6 Trafficking
Rothmeier A, Marchese P, Langer F, Kamikubo Y, Schaffner F, Cantor J, Ginsberg M, Ruggeri Z, Ruf W
ARTERIOSCL THROM VAS. 2017;37(7):1323-1331.

Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development
Subramaniam S, Jurk K, Hobohm L, Jäckel S, Saffarzadeh M, Schwierczek K, Wenzel P, Langer F, Reinhardt C, Ruf W
BLOOD. 2017;129(16):2291-2302.

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtländer M, Langer F
HAMOSTASEOLOGIE. 2017;37(4):241-255.

Tumorassoziierte venöse Thromboembolien
Voigtländer M, Langer F
Vasomed. 2017;29(3):127-134.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48]
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;146:135.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;141:39-48.

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias
Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F
ANN HEMATOL. 2016;95(6):945-57.

The impact of social factors on outcomes in patients with bleeding disorders
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(1):46-53.

The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies
Nickel K, Labberton L, Long A, Langer F, Fuchs T, Stavrou E, Butler L, Renné T
THROMB RES. 2016;141 Suppl 2:S4-7.

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
Voigtländer M, Holstein K, Spath B, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(6):e537-e544.

S2k-Leitlinie Qualitätsanforderungen in der gastrointestinalen Endoskopie, AWMF Register Nr. 021-022. Erstauflage 2015
Denzer U, Beilenhoff U, Eickhoff A, Faiss S, Hüttl P, In der Smitten S, Jakobs R, Jenssen C, Keuchel M, Langer F, Lerch M, Lynen Jansen P, May A, Menningen R, Moog G, Rösch T, Rosien U, Vowinkel T, Wehrmann T, Weickert U
Z GASTROENTEROL. 2015;53(12):E1-227.

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study
Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, Francis J, Bokemeyer C, Langer F
EXP HEMATOL ONCOL. 2015;4:22.

Atypical venous thromboses in myeloproliferative neoplasias
Dicke C, Frölich A, Holstein K, Bokemeyer C, Langer F
PHLEBOLOGIE. 2015;44(6):324–329.

Pathophysiology of Trousseau's syndrome
Dicke C, Langer F
HAMOSTASEOLOGIE. 2015;35(1):52-9.

Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy
Jacobsen C, Oechsle K, Hauschild J, Steinemann G, Spath B, Bokemeyer C, Ruf W, Honecker F, Langer F
THROMB RES. 2015;136(3):673-81.

Hämostaseologische Aspekte in der Onkologie
Langer F
HAMOSTASEOLOGIE. 2015;35(2):152-64; quiz 165.

The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Nickel K, Ronquist G, Langer F, Labberton L, Fuchs T, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou E, Ronquist G, Renné T
BLOOD. 2015;126(11):1379-89.

Thrombin generation in a patient with an acquired high-titre factor V inhibitor
Schmidt D, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F
BLOOD COAGUL FIBRIN. 2015;26(1):81-87.

Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia
Voigtländer M, Conradi L, Hinsch A, Langer F
THORAC CARD SURG REP. 2015;4(1):40-43.

Clinical Evidence that Coagulation Activation Drives Cancer Progression - a Report of 2 Cases
Voigtländer M, Holstein K, Leuenroth S, Mudter J, Bokemeyer C, Langer F
ONCOL RES TREAT. 2015;38(9):449-52.

Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Dicke C, Holstein K, Schneppenheim S, Dittmer R, Schneppenheim R, Bokemeyer C, Iking-Konert C, Budde U, Langer F
EXP HEMATOL ONCOL. 2014;3:21.

Relationship between haemophilia and social status
Holstein K, Eifrig B, Langer F
THROMB RES. 2014.

Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2014;34 (4A):5-8.

Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion
Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White J, Budde U, Bokemeyer C, Schneppenheim R
THROMB HAEMOSTASIS. 2014;111(4):777-779.

Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation
Langer F, Ruf W
THROMB HAEMOSTASIS. 2014;111(4):590-7.

Bridging: Perioperatives Vorgehen bei dauerhafter oraler Antikoagulation oder Plättchenfunktionshemmung
Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe R
DEUT MED WOCHENSCHR. 2014;139(24):1301-6.

Seltene Gerinnungsstörung oder ein Fall für den Psychiater
Zinser M, Holstein K, Langer F, Voigt P, Holzhüter J
Hamb Ärztebl. 2014;2014(11):30-31.

Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses
Amirkhosravi A, Bigsby G, Desai H, Rivera-Amaya M, Coll E, Robles-Carrillo L, Faust P, Waters A, Meyer T, Reyes E, Langer F, Francis J
BLOOD COAGUL FIBRIN. 2013;24(5):510-7.

Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy
Honecker F, Koychev D, Lühmann A, Langer F, Dieckmann K, Bokemeyer C, Oechsle K
ONKOLOGIE. 2013;36(11):663-8.

Relevant bleeding diathesis due to acquired factor XIII deficiency
Janning M, Holstein K, Spath B, Schnabel C, Bannas P, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2013;33 Suppl 1:S50-4.

Perioperative thromboprophylaxis
Langer F
VISZERALMEDIZIN. 2013;29(5):297-302.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2012;32 Suppl 1:48-51.

Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor.
Langer F, Bokemeyer C
HAMOSTASEOLOGIE. 2012;32(2):95-104.

Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B, Hansen A, Bokemeyer C, Langer F
PLATELETS. 2012;23(1):60-68.

Akute Blutungen ohne Trauma - Gerinnung checken mit System
Langer F, Holstein K, Bokemeyer C
Der Allgemeinarzt. 2011;33(15):37-40.

[Venous thrombembolism in tumour patients].
Pabinger I, Alt-Epping B, Demarmels Biasutti F, Langer F, Wörmann B, Riess H
HAMOSTASEOLOGIE. 2011;31(4):281-282.

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.
Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, Amaya M, Garber E, Francis J, Hsu Y, Amirkhosravi A
J IMMUNOL. 2010;185(3):1577-1583.

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K, Rink M, Spath B, Friedrich M, Chun F, Marx G, Amirkhosravi A, Francis J, Bokemeyer C, Eifrig B, Langer F
THROMB HAEMOSTASIS. 2009;101(6):1147-1155.

Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis.
Ingersoll S, Langer F, Walker J, Meyer T, Robson T, Amaya M, Desai H, Francis J, Amirkhosravi A
CLIN EXP METASTAS. 2009;26(7):829-837.

Thromboembolische Komplikationen - Prophylaxe und Therapie im Fokus
Langer F, Holstein K, Eifrig B, Bokemeyer C
ONKOLOGE. 2009;15:150-156.

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.
Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis J, Amirkhosravi A
J THROMB HAEMOST. 2009;7(1):171-181.

A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
Gerdsen F, Luxembourg B, Langer F, Bauersachs R, Lindhoff-Last E
BLOOD COAGUL FIBRIN. 2008;19(6):477-481.

[Haemostatic aspects in clinical oncology]
Langer F, Holstein K, Eifrig B, Bokemeyer C
HAMOSTASEOLOGIE. 2008;28(5):472-480.

Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, Brümmendorf T, Dierlamm J, Bokemeyer C, Eifrig B
ANN HEMATOL. 2008;87(6):451-457.

Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F, Chun F, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis J
THROMB HAEMOSTASIS. 2007;97(3):464-470.

Letzte Aktualisierung aus dem FIS: 23.12.2024 - 23:36 Uhr